本品为人工合成的左旋甲状腺素钠盐,作用和用途与甲状腺片相似,由于本品纯度大,制剂标准化,起效缓慢、平稳,半衰期长,体内贮量大,近似于生理激素,因此为首选的甲状腺素替代治疗药。口服平均能吸收50%。
甲状腺激素替代治疗药。用法及剂量 成人口服自每日25~50ug开始,每日1次;每2周递增50 ug,最终剂量为每日150~300ug;维持量为每日100~200ug;1岁以上小儿口服剂量为4 ug/kg.d,1岁以下每日25~50ug作为开始剂量,以后根据T4和TSH浓度进行调整(用于呆小病)。静脉注射法用于治疗黏液性水肿昏迷。
中文名 | 左旋甲状腺素钠五水合物 |
英文名 | L-thyroxine sodium salt |
别名 | L-甲状腺素钠五水物 左旋甲状腺素钠五水合物 L-甲状腺素钠盐五水化合物 3',3,5',5-四碘甲腺原氨酸钠 3',3,5',5-四碘甲腺原氨酸钠盐五水合物 O-(4-羟基-3,5-二碘苯基)-3,5-二碘-L-酪氨酸单钠盐五水合物 3-[4-(4-羟基-3,5-二碘苯氧基)-3,5-二碘苯基]-L-丙氨酸 钠盐 |
英文别名 | L-Thyroxine.Na lt,pentahydrate, L-thyroxine sodium salt SODIUM LEVOTHYROXINE PENTAHYDRATE L-thyroxine sodium pentahydrate*gamma-irradiated 3,3',5,5'-TETRAIODO-L-THYRONINE SODIUM SALT PENTAHYDRATE 3-(4-(4-hydroxy-3,5-diiodophenoxy)-3,5-diiodophenyl)-alaninmonosodiumsa 3-[4-(4-HYDROXY-3,5-DIIODOPHENOXY)-3,5-DIIODOPHENYL]-L-ALANINE PENTAHYDRATE sodium L-4-(4-hydroxy-3,5-diiodophenoxy)-3,5-diiodobenzylalaninate pentahydrate 3-[4-(4-HYDROXY-3,5-DIIODOPHENOXY)-3,5-DIIODOPHENYL]-L-ALANINE SODIUM SALT PENTAHYDRATE SODIUM (S)-2-AMINO-3-[4-(4-HYDROXY-3,5-DIIODOPHENOXY)-3,5-DIIODOPHENYL]PROPIONATE PENTAHYDRATE (S)-2-AMINO-3-[4-(4-HYDROXY-3,5-DIIODOPHENOXY)-3,5-DIIODOPHENYL]PROPIONIC ACID SODIUM SALT PENTAHYDRATE |
CAS | 6106-07-6 |
EINECS | 682-494-3 |
化学式 | C15H20I4NNaO9 |
分子量 | 888.93 |
密度 | 2.381 |
熔点 | 207-210 (dec.)(lit.) |
比旋光度 | [α]D20 +15~+19° |
溶解度 | 细胞培养基: 0.1mg/ml |
存储条件 | 2-8°C |
外观 | 粉末 |
颜色 | White to Yellow to Orange |
BRN | 5721845 |
体内研究 | Deiodinases (DIOs), which catalyse the conversion of thyroxine (pro-hormone) to the active thyroid hormone, are associated with thyroid stimulating hormone (TSH) levels. DIO1 and DIO2 catalyze activation of thyroid hormone secretion in contrast to DIO3 playing role inactivation of the secretion. Activities of DIO1 and DIO2 play pivotal role in the negative feedback regulation of pituitary TSH secretion. L-Thyroxine (T4) and Triiodothyronine (T3) hormones are known to modulate the expression of ionic channels, pumps and regulatory contractile proteins. Moreover, thyroid hormones have been shown to influence calcium homeostasis and flux responsible for excitation and contractility, with L-Thyroxine and Triiodothyronine modulating its pharmacological control and secretion. In rats fed 12 weeks with the iodine-free diet, a significant decrease in the levels of both Triiodothyronine and L-Thyroxine is observed when compared to the control group fed with standard diet (p<0.001). In the group treated with low doses of L-Thyroxine, an increase in L-Thyroxine levels is observed (p=0.02) while Triiodothyronine levels remain virtually similar to the control group (p=0.19). Rats treated with high doses of L-Thyroxine display a significant increase in both Triiodothyronine and L-Thyroxine circulating concentrations compared to the non-treated hypothyroid group (p<0.001 and p=0.004, respectively) and a significant increase in L-Thyroxine levels when compared to the control values (p=0.03). |
危险品标志 | Xn - 有害物品 |
风险术语 | 40 - 少数报道有致癌后果。 |
安全术语 | S22 - 切勿吸入粉尘。 S24/25 - 避免与皮肤和眼睛接触。 S36 - 穿戴适当的防护服。 |
WGK Germany | 3 |
RTECS | YP2833760 |
FLUKA BRAND F CODES | 3-8-10 |
本品为人工合成的左旋甲状腺素钠盐,作用和用途与甲状腺片相似,由于本品纯度大,制剂标准化,起效缓慢、平稳,半衰期长,体内贮量大,近似于生理激素,因此为首选的甲状腺素替代治疗药。口服平均能吸收50%。
甲状腺激素替代治疗药。用法及剂量 成人口服自每日25~50ug开始,每日1次;每2周递增50 ug,最终剂量为每日150~300ug;维持量为每日100~200ug;1岁以上小儿口服剂量为4 ug/kg.d,1岁以下每日25~50ug作为开始剂量,以后根据T4和TSH浓度进行调整(用于呆小病)。静脉注射法用于治疗黏液性水肿昏迷。
微信搜索化工百科或扫描下方二维码,添加化工百科小程序,随时随地查信息!